2015 

In the run up to our 2015 Drug Discovery Summit, we spoke with Juan-Miguel Jimenez, Vertex Pharmaceuticals, Araz Raoof, Janssen Pharmaceuticals and Johannes Grosse from Takeda Cambridge Ltd to discuss their thoughts about the end of the era of the blockbuster drug and what the future of drug discovery research might look like.

Johannes Grosse, Head of Cardiovascular, Inflammatory and Metabolic Disease Group, Takeda Cambridge Ltd.

Johannes joined Paradigm Therapeutics, now Takeda Cambridge, as Head of Discovery Biology in 2005. Consecutive to the acquisition of the site the workforce was expanded, and ever since he is heading the group for cardiovascular, inflammatory and metabolic diseases. In this role he directs the exploration and development of innovative targets for all aspects of the metabolic syndrome, chronic inflammatory diseases, cardiovascular and renal diseases, covering the spectrum from target validation to preclinical candidate stage. At our 16^th Annual Drug Discovery Leaders Summit Johannes will be sharing his research into appetite regulation by Insl5 – an orexigenic enteroendocrine hormone.

 Click here to read our interview with Johannes.

Juan-Miguel Jimenez, Senior Director, Head of Chemistry UK, Vertex Pharmaceuticals

Juan-Miguel joined Vertex Pharmaceuticals (UK) as senior Project Leader and subsequently appointed Head of Chemistry in 2013 where he is currently working. He has developed leadership responsibilities for Kinase projects within several therapeutic areas, including cancer, immunology and CNS. At our 16th Annual Drug Discovery Leaders Summit Juan-Miguel will share a case study of the discovery of a clinical candidate for the treatment of cancer.

Click here to read our interview with Juan-Miguel.

Araz Raoof, Scientific Affairs and Analysis, Janssen Pharmaceuticals, Belgium

Araz is currently Scientific Affairs and Analysis lead at the Janssen Pharmaceutica Research and Development campus in Belgium. Prior to this role, she was a Vice President Global Functional Head of Community of Research Excellence & Advanced Technology (C.R.E.A.Te / Discovery Sciences) at Janssen Research & Development, also at Belgium.

Click here to read our interview with Araz.